A snapshot of pediatric inpatients and outpatients with COVID-19: a point prevalence study from Turkey
dc.contributor.author | Yilmaz, D | |
dc.contributor.author | Üstündag, G | |
dc.contributor.author | Büyükçam, A | |
dc.contributor.author | Sali, E | |
dc.contributor.author | Çelik, Ü | |
dc.contributor.author | Avcu, G | |
dc.contributor.author | Belet, N | |
dc.contributor.author | Taskin, EÇ | |
dc.contributor.author | Demir, SÖ | |
dc.contributor.author | Birbilen, AZ | |
dc.contributor.author | Kiliç, Ö | |
dc.contributor.author | Akcan, ÖM | |
dc.contributor.author | Yilmaz, AT | |
dc.contributor.author | Kocabas, BA | |
dc.contributor.author | Hatipoglu, N | |
dc.contributor.author | Karbuz, A | |
dc.contributor.author | Çakir, D | |
dc.contributor.author | Sütçü, M | |
dc.contributor.author | Aygün, FD | |
dc.contributor.author | Çelik, T | |
dc.contributor.author | Sen, SB | |
dc.contributor.author | Dalgiç, N | |
dc.contributor.author | Ümit, Z | |
dc.contributor.author | Kara, SS | |
dc.contributor.author | Öncel, EK | |
dc.contributor.author | Bolat, A | |
dc.contributor.author | Çil, MK | |
dc.contributor.author | Turan, C | |
dc.contributor.author | Guzin, AÇ | |
dc.contributor.author | Topal, S | |
dc.contributor.author | Besli, GE | |
dc.contributor.author | Dogan, G | |
dc.contributor.author | Sahin, S | |
dc.contributor.author | Akin, F | |
dc.contributor.author | Bildirici, Y | |
dc.contributor.author | Dayar, GT | |
dc.contributor.author | Sari, EE | |
dc.contributor.author | Isançli, DK | |
dc.contributor.author | Kara, M | |
dc.contributor.author | Önal, P | |
dc.contributor.author | Aylaç, H | |
dc.contributor.author | Lüleci, D | |
dc.contributor.author | Yasar, B | |
dc.contributor.author | Dede, E | |
dc.contributor.author | Çaglar, A | |
dc.contributor.author | Akova, S | |
dc.contributor.author | Turgut, EA | |
dc.contributor.author | Özkaya, PY | |
dc.contributor.author | Gülmez, TK | |
dc.contributor.author | Ulusoy, E | |
dc.contributor.author | Duyu, M | |
dc.contributor.author | Kara, Y | |
dc.contributor.author | Çeliktas, H | |
dc.contributor.author | Tekeli, O | |
dc.contributor.author | Çaglar, F | |
dc.contributor.author | Gül, D | |
dc.contributor.author | Cebeci, SO | |
dc.contributor.author | Battal, F | |
dc.contributor.author | Bal, A | |
dc.contributor.author | Aygün, E | |
dc.contributor.author | Uysalol, M | |
dc.contributor.author | Arslan, G | |
dc.contributor.author | Özkavakli, A | |
dc.contributor.author | Kizil, MC | |
dc.contributor.author | Yazar, A | |
dc.contributor.author | Aygün, F | |
dc.contributor.author | Somer, A | |
dc.contributor.author | Kuyucu, N | |
dc.contributor.author | Dinleyici, EÇ | |
dc.contributor.author | Kara, A | |
dc.date.accessioned | 2024-07-18T12:08:23Z | |
dc.date.available | 2024-07-18T12:08:23Z | |
dc.description.abstract | This multi-center point prevalence study evaluated children who were diagnosed as having coronavirus disease 2019 (COVID19). On February 2nd, 2022, inpatients and outpatients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were included in the study from 12 cities and 24 centers in Turkey. Of 8605 patients on February 2nd, 2022, in participating centers, 706 (8.2%) had COVID-19. The median age of the 706 patients was 92.50 months, 53.4% were female, and 76.7% were inpatients. The three most common symptoms of the patients with COVID-19 were fever (56.6%), cough (41.3%), and fatigue (27.5%). The three most common underlying chronic diseases (UCDs) were asthma (3.4%), neurologic disorders (3.3%), and obesity (2.6%). The SARS-CoV-2-related pneumoniae rate was 10.7%. The COVID-19 vaccination rate was 12.5% in all patients. Among patients aged over 12 years with access to the vaccine given by the Republic of Turkey Ministry of Health, the vaccination rate was 38.7%. Patients with UCDs presented with dyspnea and pneumoniae more frequently than those without UCDs (p < 0.001 for both). The rates of fever, diarrhea, and pneumoniae were higher in patients without COVID-19 vaccinations (p = 0.001, p = 0.012, and p = 0.027). Conclusion: To lessen the effects of the disease, all eligible children should receive the COVID-19 vaccine. The illness may specifically endanger children with UCDs. | |
dc.identifier.issn | 0340-6199 | |
dc.identifier.other | 1432-1076 | |
dc.identifier.uri | http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/10929 | |
dc.language.iso | English | |
dc.publisher | SPRINGER | |
dc.subject | HOSPITALIZED-PATIENTS | |
dc.subject | CHILDREN | |
dc.subject | DISEASE | |
dc.title | A snapshot of pediatric inpatients and outpatients with COVID-19: a point prevalence study from Turkey | |
dc.type | Article |